IMR Press / CEOG / Special Issues / cardiovascular_complications_in_pregnancy

Cardiovascular Complications in Pregnancy

Section: Pregnancy
Submission deadline: 15 May 2023
Special Issue Editors
  • Edoardo Sciatti, MD
    Cardiology Unit 1, ASST Papa Giovanni XXIII, Bergamo, Italy
  • Rossana Orabona, MD
    Obstetrics and Gynecology Unit, ASST Spedali Civili, Brescia, Italy
Special Issue Information

Dear Colleagues,

Pre-eclampsia (PE) is one of the most common causes of maternal and foetal mortality and morbidity worldwide, and effects approximately 2-8% of all pregnancy cases. Although cardiovascular (CV) risk further increases after PE, a direct causative relationship between PE and CV has not yet been determined. It is known that pregnancy itself causes some alterations in the CV system that resolve after delivery, while those symptoms caused by PE appear to persist even after child birth. Foetal growth restriction (FGR) is related to PE, but can also be present in normotensive women, and carries an uncertain CV risk. Recently, several studies involving women without CV risk factors analysed the CV consequences of PE at short-to-medium term after delivery. Women with a history of PE, especially early-onset PE, are characterized by endothelial dysfunction, arterial stiffness, altered elastic properties of the ascending aorta, biventricular and left atrial myocardial contractility impairment, myocardial fibrosis, altered ventricular-arterial coupling, and an inappropriate left ventricular mass. All these issues help to explain, as demographical studies have already suggested, why PE is a risk factor for heart failure with preserved ejection fraction. A similar conclusion can also be drawn for FGR. However, several areas of uncertainty still exist concerning the role of the CV system in regards to causes, and consequences, of PE/FGR, as well as potential therapeutic strategies for these patients. These are the main themes of this Special Issue. 

Dr. Edoardo Sciatti and Dr. Rossana Orabona 

Guest Editors

HELLP syndrome
fetal growth restriction
heart failure
Manuscript Submission Information

Manuscripts should be submitted via our online editorial system at by registering and logging in to this website. Once you are registered, click here to start your submission. Manuscripts can be submitted now or up until the deadline. All papers will go through peer-review process. Accepted papers will be published in the journal (as soon as accepted) and meanwhile listed together on the special issue website. Research articles, reviews as well as short communications are preferred. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office to announce on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts will be thoroughly refereed through a double-blind peer-review process. Please visit the Instruction for Authors page before submitting a manuscript. The Article Processing Charge (APC) in this open access journal is 1500 USD. Submitted manuscripts should be well formatted in good English.

Back to top